uBiome Will Expand World’s Largest Human Microbiome Database and Advance Product Portfolio, Including Drug Discovery & Development SAN FRANCISCO, September 21, 2018-- uBiome, the leader in microbial genomics, today announced the Company has raised $83 million in Series C financing. OS Fund led the round, with participation from 8VC, Y Combinator, Dentsu Ventures, and additional new and existing investors. The microbiome plays a vital role in every aspect of health – it has been correlated with a wide range of conditions and can provide insights into predispositions to diseases ranging from inflammatory bowel disease to metabolic disorder to cancer.